San Antonio · Seed–Series A · 6 people tracked
Find your way into Targeted Technology Funds
350 people in our graph share verified history with the Targeted Technology Funds team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Targeted Technology Funds invests in early-stage life science and healthcare companies whose technologies can advance the practice of medicine and improve patient outcomes, as well as those that enhance the efficiency, cost, or functionality of developing and manufacturing life science products. The firm favors innovations with shorter time and lower cost to market that address compelling market needs offering the opportunity for enhanced returns. Investments span a broad range of healthcare categories, with particular emphasis on medical devices, life science tools, biotechnology, diagnostics, and specialty pharmaceuticals. The firm views its model as well suited to a healthcare environment that rewards better clinical outcomes and reduced costs.
Source: firm website, verified Aug 3, 2026.
Team · 6 people
from public directories
Founder mafia
2 people who came through Targeted Technology Funds went on to found or lead other companies.
What they invest in
from 9 of 24 portfolio companiesHealthtech ×6Medical Devices ×5Biotech ×4Longevity ×1Robotics ×1Sports Tech ×1
HQs:United States×10United Kingdom×1
Investments · 24 tracked
founders shown can be your intro pathBy year:2026 · 12018 · 12015 · 22014 · 12012 · 16 dated
Smith+Nephew is a medical technology company that develops products for the repair, regeneration, and replacement of soft and hard tissue, including sports medicine solutions for treating sporting injuries.
HealthtechMedical DevicesSports TechLondon, GB
Thomas James Smith(Founder)Horatio Nelson Smith(Co-founder)Deepak Nathin
PartnerAlan Dean· solo GP
Co-investorsAccelmed PartnersAccess Venture PartnersAlphaDriveaMoonPeregrine Ventures
Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.
HealthtechMedical DevicesMountain View, US
Matt Brokaw(CEO & President)inDerrick Sung(Executive Officer)inMatthew Salkeld(Executive Officer)Irina Ridley(Executive Officer)inAndre Cheng(Executive Officer)inFred Dinger(Executive Officer, Director)in
PartnerAlan Dean· solo GP
Co-investorsLaunchCapitalOrbiMedQuesta CapitalAlly Bridge GroupHorizon
PartnerAlan Dean· solo GP
Provides technologies for detection, neutralization, and removal of endotoxin for bioresearch and bioprocess markets.
PartnerAlan Dean· solo GP
Developing the Surfacer Inside-Out Access Catheter System, a novel approach to central venous access.
San Antonio, US
James Clifton(Executive Officer)
BoardAlan Dean(Director)James Traa(Director)Robert Coleman(Director)
PartnerAlan Dean· solo GP
Bluegrass Vascular develops medical devices for restoring venous access in chronically occluded veins using an inside-out catheter approach.
HealthtechMedical DevicesLexington, US
BoardJohn Gurley(M.D.)
PartnerAlan Dean· solo GP
Medical technology company focused on tissue regeneration and repair using proprietary scaffold materials.
PartnerAlan Dean· solo GP
Co-investorsUT Horizon Fund
BiotechSan Antonio, US
James R. Garvin(Chief Executive Officer, President, Secretary and Treasurer)
PartnerAlan Dean· solo GP
BiotechHouston, US
Frank Tufaro(Executive Officer, Director)Brian Mooney(Executive Officer)Isaac Cheng(Director)
BoardDaniel Watkins(Director)Reenie McCarthy(Director)Drew Pardoll(Director)
PartnerAlan Dean· solo GP
Co-investorsTexas Ventures
HealthtechSan Antonio, US
Dennis F. Filips(Executive Officer, Director)inDavid Schneider(Executive Officer, Director)Maggie Pemberton(Executive Officer)inIan Atkinson(Executive Officer, Director)inPhilip W. Faris(Executive Officer, Director)
BoardPaul Castella(Executive Officer, Director)in
PartnerAlan Dean· solo GP
Medical device company providing the neoClose Trocar Port Closure System for laparoscopic and minimally invasive surgery.
PartnerAlan Dean· solo GP
Oxnard, US
Vito SAN FILIPPO(Executive Officer)MARIANNE THERESA CRONIN(Executive Officer, Director)
PartnerAlan Dean· solo GP
PartnerAlan Dean· solo GP
StemBioSys develops cell culture technology, including the patented CELLvo Matrix that replicates the body's physiological microenvironment to expand mesenchymal stem cells and specialty cells while preserving their stem-like properties.
BiotechHealthtechLongevityMedical DevicesSan Antonio, US
Chen Xiao-Dong(Director)Steven Davis(Co-founder)Xiao-Dong Chen(Co-founder)Travis Block(Chief Technology Officer)Jean Cheever(Director)Mark D Horsey(Executive Officer)
PartnerAlan Dean· solo GP
Developer of an intraosseous medicine technology platform; acquired by Teleflex in 2013.
PartnerAlan Dean· solo GP
Co-investorsTullis Health Investors
Xenex builds pulsed Xenon UV light disinfection robots that deactivate pathogens missed during manual cleaning, used by hospitals to reduce environmental contamination and healthcare-associated infections.
HealthtechMedical DevicesRoboticsSan Antonio, US
Mark (Tuck) Stibich(Co-founder)Julie Stachowiak(Co-founder)Morris Miller(Co-founder & CEO)in
PartnerAlan Dean· solo GP
Co-investorsBattery VenturesTectonic VenturesEssex Woodlands Healthcare Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
3DBiO2 Medical, Inc.CytoBioscienceENTrigue Surgical, Inc.Santalis Pharmaceuticals, Inc.Soluble Bioscience, LLCViroXis Corporation, Inc.Xenex Disinfection Services
Exits · 7
1 IPOs · 6 acquisitionsSmith+NephewNYSE: SNNBiO2 Medical, Inc.acq. by Mermaid Medical GroupENTrigue Surgical, Inc.acq. by Smith+NephewSantalis Pharmaceuticals, Inc.acq. by TFSSoluble Bioscience, LLCacq. by InventaBioTechVidacareacq. by TeleflexViroXis Corporation, Inc.acq. by TFS
Portfolio news
latest coverage across their companiesXenex · infectioncontroltoday.com · Jul 24, 2026
Frequently asked questions
- How many investments has Targeted Technology Funds made?
- Targeted Technology Funds has 24 tracked investments, 7 of which have exited, including 1 dated in the last 24 months.
- What stage does Targeted Technology Funds invest at?
- Targeted Technology Funds invests at the Seed, Series A stages.
- What sectors does Targeted Technology Funds focus on?
- Targeted Technology Funds focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is Targeted Technology Funds located?
- Targeted Technology Funds is headquartered in San Antonio, US.
- Who does Targeted Technology Funds co-invest with?
- Targeted Technology Funds most often shares deals with Battery Ventures, OrbiMed, Peregrine Ventures, among 12 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.